Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...

R-DXd has previously shown promising clinical results in platinum-resistant ovarian, peritoneal, and fallopian tube cancers.

Peritoneal mesothelioma is a disease in which cancerous cells form in the peritoneum, which is the lining of the abdomen. Mesothelioma can also occur in the chest and scrotum. Many other health ...

Actor Nafisa Ali has revealed that her ovarian and peritoneal cancer has returned, and she will now undergo chemotherapy ...

Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with platinum-resistant ...

The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, ...

Raludotatug deruxtecan has received breakthrough therapy designation for treatment of certain adults with platinum-resistant ...

Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a type ...

The impact of guidelines on the treatment of endometrial cancer in Germany: A nationwide analysis of the AGO in 2006 and 2009. Background: To compare survival outcome and identify differences in ...

The US FDA has granted breakthrough therapy designation to the novel antibody-drug conjugate (ADC) raludotatug deruxtecan ...

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of ...